

Metallomics

Accepted Manuscript




This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

**EVALUATION OF THE BIOLOGICAL EFFECT OF Ti GENERATED DEBRIS
FROM METAL IMPLANTS: IONS AND NANOPARTICLES.**

28 J. Soto-Alvaredo,¹ E. Blanco,¹ J. Bettmer,¹ D. Hevia,² R. M. Sainz,² C. López Cháves,³ C.
29 Sánchez,³ J. Llopis,³ A. Sanz-Medel¹ and M. Montes-Bayón.^{1*}
30
31

32
33
34
35
36

¹ Department of Physical and Analytical Chemistry, Faculty of Chemistry. University of Oviedo. C/ Julián Clavería 8, 33006 Oviedo. Spain

37
38
39
40
41

² Department of Morphology and Cell Biology, Faculty of Medicine. Cancer Research Institute of Principado de Asturias (IUOPA). University of Oviedo. C/ Julián Clavería 6, 33006 Oviedo. Spain

42
43
44
45

³ Department of Physiology, Faculty of Pharmacy. University of Granada. Campus de Cartuja. 18071 Granada. Spain.

ABSTRACT

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Metallic implants placed in human's exhibit wear and corrosion that yield in the liberation of metal-containing by-products. In the case of titanium (Ti) containing implants, the metal containing debris may exist in a number of states, including metallic particles produced by mechanical wear and the products of metal corrosion in biological environments, such as the joints and surrounding fluids and tissues. In addition, these constituents may dissolve in both intracellular and extracellular solutions generating Ti ions. Both species, ions and nanoparticles show different cellular toxicity. In this work we have evaluated the possible evolution of TiO₂ nanoparticles (NPs) to soluble Ti metal ions by contact with biological fluids. For this aim, an *in vitro* study to address quantitative Ti solubilisation from TiO₂ nanoparticles (with a diameter of 21 nm) after incubation with human serum at different concentrations has been conducted. Total Ti determination revealed low solubilisation rates ranging from 0.53 to 0.82 % after just one week of incubation in the serum. The incubated serum was then subjected to speciation analysis by anion exchange liquid chromatography using inductively coupled plasma mass spectrometry (ICP-MS) as elemental detector for Ti monitoring. The obtained results revealed a significant increase in the Ti signal associated to the fraction of the protein transferrin and preferentially to one of the metal binding sites of the protein, the N-lobe. Thus, the effect of Ti at the cellular level has been evaluated by considering that it can be present either as ions or as nanoparticles using two different cells lines: human enterocytes HT29 and murine osteoblasts MC3T3. Significant toxicity was found at the highest concentration assayed (50 µg mL⁻¹) for both Ti species (ions and NPs) and slightly higher for the ionic species at lower concentrations (1 and 10 µg mL⁻¹).

Key-words: titanium, TiO₂ nanoparticles, Ti(IV) ions, toxicity, ICP-MS, HPLC.

INTRODUCTION

1
2
3
4
5 Immediately after implantation in the human body all implants start to degrade through
6
7 two mechanisms: corrosion and wear. Wear is a mechanical/physical degradation of
8
9 materials (producing particles) whereas corrosion is a chemical (or electrochemical) form
10
11 of degradation (mainly producing solubilized metal ions).¹ Thus, the use of titanium alloys
12
13 for biomedical applications has introduced the possibility of generating microscopic Ti
14
15 particles together with Ti metal ions that are present in the tissues of the surrounding
16
17 implants (peri-implant environment).^{2,3} The particles are commonly of nanometer size
18
19 (nanoparticles, NPs) and activate macrophages that increase bone absorption and,
20
21 eventually, inflammatory reactions leading to the implant failure.⁴ In addition, there is
22
23 growing evidence that metal debris can directly affect cells of the osteoblast lineage.^{5,6} As
24
25 previously stated, all metal implants *in vivo* undergo corrosion which results also in the
26
27 additional production of metal ions that reach, eventually, the circulatory system. The
28
29 behavior of metal ion released into biofluids can be diverse, showing combination with
30
31 biomolecules (e.g. proteins) or with a water molecule or an anion to form an oxide,
32
33 hydroxide, or an inorganic salt.⁷ Metal liberation from metallic implants has been reported
34
35 in the body fluids of patients carrying metal on metal total hip replacements,⁸
36
37 intramedullary nails⁹ and, more recently, in patients undergoing instrumented spinal
38
39 arthrodesis.¹⁰ Locally, these metal ions might also enter the cells and alter intracellular
40
41 processes.^{11 12}
42
43
44
45
46

47 As previously described, the release of metal ions and nanoparticles to the peri-
48
49 implant environment should not be considered as independent phenomena since they
50
51 might occur simultaneously. In fact, metal ions detected in the biological fluids of patients
52
53 carrying metallic implants can be additionally coming from the partial dissolution of
54
55 released NPs.¹³ Although few documents exist on this topic, the formation of metal ions
56
57
58
59
60

1
2
3 from dissolution of NPs has been documented by several authors, for instance, having Ag
4 or NiO-NPs.^{14, 15} In these cases, the rate of dissolution depends not only on the type of
5 nanoparticle but also on the particle size, concentration and surface functionalization. In
6
7 addition, the temperature and the nature of the immersion medium (e.g., the presence of
8 salts or binding biomolecules) will be major factors affecting the dissolution of NPs. In
9
10 the case of Ti alloy implants, the production of nanoparticles (<50 nm) has been observed
11
12 in the synovial fluids and peri-prosthetic tissues of patients.¹⁶ The Ti ions dissolved from
13
14 the oxide nanoparticles (e.g. TiO₂) originated from wear as well as the Ti ions directly
15
16 produced by corrosion of the implant will influence biological characteristics of the cells
17
18 in contact with the peri-implant environment; thus, it is necessary to measure the ion
19
20 concentration in the nanoparticle dispersion. Particularly the determination of released
21
22 metal ions from nanoparticles dispersion is very important for the evaluation of the
23
24 cytotoxicity of nanoparticles.¹⁷

25
26
27
28
29
30
31
32 Thus, the present work tries to evaluate, comparatively, the toxicological effect of
33
34 Ti ions and Ti nanoparticles, which might be released from alloy implants in cell cultures
35
36 of murine osteoblasts (bone cells). However, in order to evaluate if both situations can be
37
38 treated independently, it is also necessary to address the putative presence of Ti ions
39
40 released from titanium dioxide nanoparticles (TiO₂) once in contact with biological fluids
41
42 (e.g. human serum). For this purpose, TiO₂ NPs (21 nm) were dispersed in human serum
43
44 and after some days of incubation with mechanical stirring, the metal ions released were
45
46 evaluated by total Ti determination using ICP-DF-MS (inductively coupled plasma-
47
48 double focusing-mass spectrometry). Further studies to elucidate if some of the released
49
50 Ti is associated to the main serum proteins metal speciation were conducted by anion
51
52 exchange chromatography coupled on-line to ICP-DF-MS. In order to assess differential
53
54 cell toxicity, proliferation and viability tests were used to evaluate the effect of TiO₂ NPs
55
56
57
58
59
60

1
2
3 and Ti (IV) ions in murine MC3T3 osteoblasts (bone cells that be directly exposed to the
4 ions or particles produced during the implant surface degradation) and in HT29
5 enterocytes (intestinal cells and main route of absorption of most metals in the organisms)
6 that could be in contact with the NPs due to their dissemination in the organism. The
7 study was completed by confirming the incorporation of the TiO₂ NPs in the cells by
8 endocytosis using transmission electron microscopy (TEM).
9
10
11
12
13
14
15
16
17

18 **EXPERIMENTAL**

19 **Instrumentation.**

20
21 A double focusing-sector field ICP-MS (ICP-DF-MS) instrument, ELEMENT II (Thermo
22 Fischer Scientific, Bremen, Germany), was used for the total Ti determination using
23 medium resolving power ($m/\Delta m=3000$). The instrument was equipped with a Meinhard
24 concentric glass nebuliser and with nickel sampler and skimmer cones. Titanium
25 monitoring was conducted at m/z 47 and m/z 49 using standard plasma operating
26 conditions described somewhere else.⁹ The transmission electron microscope (TEM) used
27 was a Carl Zeiss (Oberkochen, Germany) (model Libra 120 Plus).
28
29
30
31
32
33
34
35
36
37

38
39 HPLC separations were carried out using a dual piston liquid chromatographic
40 pump (Shimadzu LC-10AD, Shimadzu Corporation, Kyoto, Japan) equipped with a
41 sample injection valve Rheodyne, Model 7125 (Cotati, CA, USA), fitted with a 100 μ L
42 injection loop, and an anion-exchange column, Mono-Q HR 5/5 (50 x 5 mm id, Pharmacia,
43 Amersham Bioscience, Spain). The chromatographic conditions and mobile phases are
44 similar to those previously described.⁹ In summary, the separation involves a gradient of
45 ammonium acetate (linear from 0 to 50%B in 15 min) at 1 mL/min. The exact
46 composition of the mobile phases is described below. Before injection, serum was diluted
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (1+1) in mobile phase A. This gradient permits the separation of the most abundant serum
4
5 containing proteins (IgG, transferrin and albumin) with adequate resolution.
6

7 8 **Chemicals**

9
10 TiO₂-NPs (21 nm) were purchased from Sigma Aldrich (St. Louis, MO, USA). A stock
11
12 suspension of TiO₂-NPs of 1 mg/mL was prepared in deionized Milli-Q water (Millipore
13
14 Bedford, MA, USA) and sonicated for 15 min in an ultrasonic bath. Further dilutions were
15
16 prepared for incubation with serum samples or addition to the cell cultures.
17

18
19 Mobile phases for HPLC containing: A) 50 mM tris-aminomethane (Merck,
20
21 Darmstadt, Germany)/acetic acid (Merck), pH 7.4 and B) A + 1.5 M ammonium acetate
22
23 (Merck) were prepared by dilution of the solid salts with the 18 MΩcm distilled de-
24
25 ionized water.
26

27
28 Ti (IV) solubilisation in a compatible form for cellular studies was accomplished
29
30 by formation of a non commercial Ti-citrate complex with a 1:3 stoichiometry,
31
32 ([Ti(cit)₃]⁸⁻) that was formed by using of Ti(IV) tetrachloride and citric acid monohydrate
33
34 as described somewhere else.¹⁸ The two solutions were mixed and the final pH was
35
36 adjusted to 2.0 with the slow addition of dilute ammonia. Once the Ti (IV) complex was
37
38 formed, the addition of the growing media (at physiological pH 7.4) did not originate any
39
40 Ti visible precipitation.
41
42

43 44 **Samples**

45
46 For this study, serum samples from patients from the Hospital Universitario Central de
47
48 Asturias (HUCA) have been provided. Samples were collected in accordance with
49
50 protocols approved by the relevant institutional review boards (HUCA) and with the
51
52 Declaration of Helsinki. They were taken in five millilitres vacutainer tubes (Greiner
53
54 bioone, Madrid, Spain) for trace elements. The precautions taken to avoid metal
55
56 contamination during blood extraction have been described somewhere else⁸ and those
57
58
59
60

1
2
3 procedures were followed here. Samples were pooled to obtain a large sample volume and
4
5 divided into different aliquots of 5 mL (for incubation with different TiO₂ NPs). For
6
7 incubation with different TiO₂ concentrations (to achieve a final Ti concentration around
8
9 10, 30 and 50 µg/mL), the serum samples were maintained at room temperature (21 ± 2
10
11 °C) and continuously shaking for 7 days. Then, the nanoparticles were separated by
12
13 centrifugation of the nanoparticle suspensions for 30 min at 12,000 g and then filtrated
14
15 through 0.45 µm. The supernatant containing the ions released from nanoparticles was
16
17 analysed by ICP-MS using a previously optimized methodology based on isotope dilution
18
19 analysis.⁹
20
21

22 **Cell cultures**

23
24 MC3T3 murine osteoblasts purchased in Sigma Aldrich were cultured in Alpha-Minimum
25
26 Essential Medium (α-MEM) (Sigma), supplemented with 10% foetal bovine serum and
27
28 1% penicillin/streptomycin (PS) in a humidified incubator (37°C and 5% CO₂) and media
29
30 was replaced every other day. Cells were seeded in 96 well plates and attached overnight
31
32 prior exposure to TiO₂ NPs or Ti(IV) solutions. Cells not being incubated with Ti species
33
34 served as the control group throughout each assay.
35
36
37

38
39 Human colorectal adenocarcinoma cell line HT29, originally isolated from a colon
40
41 cancer in a 72-year-old Caucasian male, was provided by the cell bank of the University
42
43 of Granada (Spain). It was cultured in RPMI 1640 medium (Sigma) supplemented with
44
45 10% heat-inactivated foetal calf serum (FCS), 10,000 units/mL penicillin and 10 mg/mL
46
47 streptomycin. The cell line was maintained in a humidified atmosphere with 5% CO₂ at
48
49 37 °C. Cells were passaged in a solution containing 0.05% trypsin and 0.5 mM
50
51 ethylenediaminetetraacetic acid (EDTA) (Sigma). Similarly to the MC3T3 cell line, the
52
53 HT29 cells were treated independently with TiO₂ NPs or Ti(IV) solutions as described
54
55 below for toxicity studies.
56
57
58
59
60

Cell viability and cytotoxicity assays

Two different assays have been used to address cellular viability in the different cell lines: the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reduction and trypan blue ((3Z,3'Z)-3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)di(1Z)hydrazin-2-yl-1-ylidene] bis (5-amino-4-oxo-3,4-dihydronaphthalene-2,7-disulfonic acid) assays. The MTT assay is based on the conversion of tetrazolium salt by mitochondrial dehydrogenases and is normally used to address cell viability. This method was complemented with the Trypan blue method also used to determine cell viability. In this latter method, the blue colorant crosses cell membranes only if cell membranes are compromised while intact cell membranes are not bypassed. That is, viable cells are not stained. For these assays a total of 9×10^4 cells/mL were seeded in 96-well plates. Cells were grown until confluence. Then, different concentrations of sterile solutions of TiO₂ NPs or Ti(IV) ions containing 0.01, 0.1, 1, 10 and 50 µg/mL were added to each well. Cells were incubated for 24 h at 37 °C in a humidified incubator with 5% CO₂. Solutions containing NPs TiO₂ were placed in an ultrasonic bath for half hour before adding them to the cell cultures in order to minimize aggregation effects. After treatment with the NPs, the medium was changed, and the cells were incubated with 0.5 mg/mL MTT (Sigma-Aldrich) or trypan blue (Sigma-Aldrich) under normal culture conditions for 4 h. Subsequently, the medium was removed and 200 µL DMSO was added to each well. The plates were shaken for 10 min and the absorbance of each solution was measured at 490 nm via a spectrophotometer (BioTek, Elx 800, Winooski, VT, USA). Absorbance values were also corrected with a NP blank.

Hoechst assay was used to determine TiO₂ NP cytotoxicity because trials with more than one assay are recommended to determine cell viability and cytotoxicity. For the Hoechst assay, cells were seeded in a 96-well plate at a density of 25,000 cells/mL of

1
2
3 complete media. They were allowed to attach overnight and then incubated with the
4 solutions of TiO₂ NPs or Ti(IV) ions containing 0, 0.01, 0.1, 1, 10 and 50 µg/mL of metal
5 for the times indicated. After 48 hours, media was removed and cells were frozen at -80°C.
6
7 After thawing, 100 µL of Milli-Q water was added to each well and cells were incubated 1
8 hour at RT. After that, cells were frozen once more to ensure cell lysis. Finally, cells were
9 incubated with 20 µg/mL of Hoescht 33258 in TNE buffer (10 mM Tris pH 7.4, 2 M
10 NaCl) for 1 hour at 37°C. Fluorescence was measured in an automatic microplate reader
11 (µQuant, Biotek, Winooski, VT, USA) at 350nm excitation/ 460nm emission filters.
12
13 Results are the media of six samples.

14
15
16 For cell cytotoxicity experiments, the data were expressed as the mean ± the
17 standard deviation (SD). Data comparisons were performed using a standard analysis of
18 variance (ANOVA). A value of P<0.001 was considered significant for the experiments
19 conducted with the MTT, trypan blue and Hoechst assays. Every experiment was repeated
20 at least five to seven times.

21 22 23 **TEM studies**

24 For the TEM studies, HT29 enterocytes were cultured at 37°C in 96-well plates as
25 described above. After 24 h, the cells were treated with TiO₂ NPs (10 and 100 µg/mL,
26 moderately cytotoxic doses) for another 24 h and then fixed with glutaraldehyde and
27 formaldehyde at 4°C for 1 h. All this experiments followed the sample preparation
28 protocol described by Megías et al.¹⁹

29 30 31 **RESULTS AND DISCUSSION**

32 33 34 ***Ti ion release from TiO₂ NPs***

35 As described in the introduction, metal ions release from nanoparticles can be a cause of
36 concern when evaluating their cytotoxicity since this can be ascribed to two different
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 sources: the physico-chemical nanoparticles-derived effect due to their high mass specific
4 surface (related to the NPs size) and the effect of dissolved metal ions solubilised from the
5 NPs. In order to evaluate the dissolution power (in terms of ion release) and complexation
6 capabilities of human serum in contact with NPs, TiO₂ NPs (21 nm) were dispersed
7 initially in water and then mixed with human serum at three different final concentrations
8 of 10, 30 and 50 µg/mL. These concentrations were selected by taking into account the
9 literature with respect to the concentration of particles in the peri-implant environment of
10 patients carrying metallic implants.²⁰ The TEM picture of the mixture (containing 50
11 µg/mL TiO₂) is shown in Figure 1. It can be seen that even under these conditions the
12 TiO₂ NPs agglomerate in small clusters, as previously described by other authors,²¹ where
13 the approximate 21 nm diameter of each particle can be observed. As compared with
14 particles solubilisation in water (data not shown), human serum proved to be superior as
15 dispersing media. The existing literature in this regard is in agreement with this finding
16 and ascribes this fact to the presence of high abundant serum proteins (e.g. albumin) that
17 may all compete for the limited space on nanoparticles surface and so contribute to a
18 better disaggregation of the nanoparticles in solution.^{21, 22}

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38 To evaluate metal ion release, triplicates of the dispersed TiO₂ NPs (10, 30 and 50
39 µg/mL) in serum were analyzed and provided solubilised Ti concentrations that can be
40 seen in Table 1. In this case, the blank of the serum before addition of the TiO₂ NPs
41 contained 1.5 ± 0.3 ng/mL (n=3) of Ti. After incubation, this concentration increased but
42 obtaining released percentages below 1% (in respect to the incubated Ti concentration as
43 TiO₂ NPs) in all cases after 7 days. These results are consistent with the fact that Ti
44 implants (normally covered by a passivation layer to form the oxide, e.g. TiO₂) are
45 relatively inert in the body when compared with other like CrCoMo alloys and therefore
46 only a very small fraction of Ti is released into the biofluids.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 One question arising from the previous results regards to the nature of the
4 solubilised Ti after incubation since this could be still due to the presence of dispersed
5 TiO₂ NPs of smaller diameter than the initial ones (e.g. covered by the protein corona) to
6 increase solubilisation. To further address the nature of the observed solubilised Ti,
7 speciation studies using anion exchange chromatography and ICP-MS detection were
8 performed. Thus, the serum samples before and after incubation with the TiO₂ NPs were
9 diluted (1+1) in the mobile phase and injected into the chromatographic system as
10 described elsewhere.⁹ Figure 2 shows the chromatographic profile of the serum sample
11 with the different monitored isotopes after incubation (³⁴S, ⁵⁷Fe and ⁴⁹Ti using resolving
12 power $m/\Delta m=4000$). This chromatography permits the separation of the most abundant
13 serum containing proteins with adequate resolution (IgG at 2 min, transferrin different
14 isoforms between 18 and 22 min and albumin at 27 min). Here is possible to observe a
15 single Ti peak (dark blue trace) corresponding the retention time of the protein transferrin
16 (Tf) (22 min) in which Fe (green trace) and sulphur (pink trace) can also be observed. As
17 reported in our previous publication,²³ Ti is found here preferentially associated to a single
18 lobe of Tf (N-lobe) in contrast to Fe that shows an equal distribution between lobes (at
19 20.5 and 22 min respectively).

20
21
22 According to previous post-column isotope dilution experiments,²³ the column
23 recovery for Ti-Tf associations can be considered quantitative. In this case, the Ti detected
24 in the Tf fraction should correspond to a concentration of approximately 78 ng/mL
25 (considering the total Ti concentration determined before and the fact that serum is diluted
26 1+1 before chromatographic injection). However, the observed Ti signal turned out to be a
27 concentration below 5 ng/mL of Ti (too low even considering the low abundance of the
28 monitored Ti isotope, 5.41%, and the medium resolution necessary to resolve the
29 polyatomic interferences in the ICP-MS). Thus, it appears that the total Ti determined in
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 solution previously (158 ng/mL) could correspond to both Ti species: metal ions that get
4
5 complexed with serum components (Tf in particular) and smaller nanoparticles that
6
7 remained in solution stabilized by the proteins present in that media (they would not elute
8
9 in the chromatographic system). However, this is the first time, to our knowledge, that the
10
11 presence of metal ions associated to proteins can be seen in serum after incubation with
12
13 TiO₂ NPs although at low solubilisation rate. Therefore, the slow solubilisation of TiO₂
14
15 NPs in the peri-implant environment could be the cause of the increased Ti concentrations
16
17 in the blood of patients with Ti implants, which remain relatively constant with time in
18
19 most of the patients.⁹
20
21
22
23
24

25 *Cell viability and cytotoxicity studies*

26
27 As we have observed, the release of Ti ions can occur either directly from the implant
28
29 surface or after previous production of nanometre size particles that show a high surface
30
31 area for electrochemical dissolution. Therefore, the presence of both species (ions and
32
33 particles) is expected at the bone-implant interface and thus, their toxicity has to be
34
35 evaluated in cell cultures, particularly, in MC3T3 murine osteoblasts and HT29
36
37 enterocytes. For this purpose, the previously used TiO₂ NPs were, in this case, dispersed
38
39 in the growing media (at different concentrations as described in the experimental section)
40
41 and the cell viability and proliferation studies were conducted. As previously reported,
42
43 NPs aggregations were observed also in the cell culture media as can be seen in the
44
45 corresponding TEM pictures observed for HT29 enterocytes of Figure 3. Figure 3A shows
46
47 the cells and the cell growing media while Figure 3B and 3C show two magnifications of
48
49 two specific areas. Figure 3B shows the particles partially agglomerated in the cell
50
51 medium as well as the interface between the cellular membrane and the growing media
52
53 where a small vesicle of NPs crossing the cell membrane can be observed (marked with a
54
55
56
57
58
59
60

1
2
3 red circle). On the other hand, Figure 3C shows clearly the presence of these particles
4 close to the Golgi apparatus containing TiO₂ agglomerates. These TEM observations
5 indicate cellular vesicle formation after treatment with TiO₂ NP as almost all metal oxide
6 NPs can be endocytosed by cells.²⁴ Endocytosis occurs through different mechanisms,
7 including phagocytosis, pinocytosis and receptor-mediated endocytosis. The formation of
8 a coated vesicle, clearly visible by TEM, indicated that the uptake of TiO₂ NPs occurred
9 most likely via receptor-mediated endocytosis.^{6,25}

10
11
12 In order to assess the level of NPs incorporation into such cells, a mass balance was
13 established for the HT29 cell cultures exposed to the TiO₂ NPs (0.1, 1 and 10 µg/mL).
14 Then, those cells were digested (in HNO₃ + H₂O₂ mixture) and analysed for total Ti by
15 ICP-MS. Incorporation values calculated based on theoretical Ti concentration spiked to
16 the cell media ranged from 2.3 to 3.8% for the three concentrations assayed and
17 considering similar number of cells. Of course, using this ICP-MS methodology can not
18 be differentiated from NPs or Ti metal ions inside the cells. In this regard, analytical
19 methodologies that permit species identification within cell cytosol should be designed
20 and evaluated for a deeper insight into the obtained toxicological data.

21
22
23 On the other hand, the same type of cells were then exposed to solubilised Ti (IV)
24 metal ions in order to compare the possible differential cytotoxicity of species. A
25 challenging part is the required synthesis of a stable Ti(IV) solution that could be added to
26 the cell culture medium for toxicity studies. It is worth mentioning that in the absence of
27 complexing molecules (for instance serum proteins), Ti (IV) tends to hydrolyse and
28 precipitate even at low pH values. In order to stabilize the ion in solution, complexation
29 with biologically present anions, e.g. citrate has been recommended by other authors.¹⁸
30 Thus, Ti(IV) citrate was prepared according to the literature to obtain [Ti(cit)₃]⁸⁻ (which
31 seems to be stable at a pH range from 5.5 to 7.5) using Ti(IV) tetrachloride as Ti source
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and the appropriate excess of citrate and then added to the cell medium. Since 10% heat-
4
5 inactivated foetal calf serum is present in the medium (which contains high concentration
6
7 of transferrin), it is very likely that Ti is then forming the Ti-transferrin complex
8
9 previously detected in human serum. As a negative control, the same concentration of
10
11 citrate was also added to the cell medium without Ti(IV). The obtained results are
12
13 summarized in Figure 4 (4A, MTT assay, 4B, Trypan blue and 4C Hoechst assay) for
14
15 MC3T3 osteoblasts (even if similar results were observed using HT29 enterocytes as well,
16
17 data not shown here).
18
19

20
21 The MTT experiments in MC3T3 osteoblasts revealed that the cell viability does
22
23 not seem to be compromised at the concentrations assayed for TiO₂ NPs. However, there
24
25 is a significant decrease in the number of viable cells in the case of using [Ti(cit)₃]⁸⁻ at 50
26
27 µg/mL (see Fig. 4A). These results were confirmed by the trypan blue experiments since
28
29 some authors have claimed that maybe the MTT assay was not suitable to address the
30
31 cytotoxicity of TiO₂ NPs²⁶. Trypan blue results can be seen in Figure 4B for both,
32
33 [Ti(cit)₃]⁸⁻ and TiO₂ NPs where we can observe a significant decrease in cell viability at
34
35 50 µg/mL (statistically significant, p<0.001). In addition, in the case of the trypan blue
36
37 assay, this effect can be observed already at 10 µg/mL. These results agree well with
38
39 previous experiments reported by others where cell toxicity was detected also at 5 and 50
40
41 µg/mL.²⁷ It is important to note that Ti concentrations under evaluation were selected here
42
43 to be physiologically relevant considering the existing literature about the metal released
44
45 by metallic implant into the peri-implant environment.²⁸
46
47
48

49
50 Finally, cellular proliferation was assessed by the Hoechst assay and results (Fig
51
52 4C) indicate two different effects for TiO₂ NPs: a significant decrease on cell proliferation
53
54 seems apparent at higher concentrations (10 and 20 µg/mL) for both Ti species while at
55
56 the lowest concentrations (0.01 µg/mL) a significant increase in cell proliferation, above
57
58
59
60

1
2
3 the control levels ($p < 0.001$), was noticed. Some authors have ascribed these results to the
4 incorporation in the cells, together with TiO_2 NPs, of a protein shell (protein corona)
5 which, in the acidic media of the endosomes might induce the release the adsorbed
6 proteins with a final improvement of cell growing and mitochondrial activities.²² When
7 the concentration of TiO_2 NPs is higher, this effect can not counterpart the toxicity effect
8 due to the NPs themselves and the cellular proliferation decreases slowly with the
9 concentration.
10
11
12
13
14
15
16
17

18 In the case of the ionic form for Ti, the effects start to be observed at 10 $\mu\text{g}/\text{mL}$ but
19 this concentration generates a decrease on cell proliferation of about 40% with respect to
20 the control and goes above 50% at 50 $\mu\text{g}/\text{mL}$. In any case, our cell viability and
21 proliferation experiments indicate that both, dissolved ions and NPs may pose an
22 important toxicity risk at Ti concentration levels of $\mu\text{g}/\text{mL}$, levels that have been reported
23 in some peri-implant tissues.²⁹ It is important to notice that Ti ions show, in our
24 experiments, higher toxicity to cells than the NPs at similar Ti levels. Thus, the
25 electrochemical corrosion of Ti implants in the human body seems to pose a higher
26 toxicity stress than the mechanical wear products originated by frictions (which are
27 expected to be the main source of Ti NPs).
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 CONCLUSIONS

44 The use of combined elemental mass spectrometry (ICP-MS, in particular),
45 spectrophotometry (for cell toxicity) and microscopy (TEM) has permitted to dig a little
46 deeper on the effect of Ti generated debris from metal implants in biological systems.
47 First, the ICP-MS quantitative measurement of the incubated TiO_2 NPs with human serum
48 samples has revealed some solubilisation of the Ti, partially in the form of metal ions and
49 part as small size NPs that remain disaggregated in solution. The released metallic ions
50
51
52
53
54
55
56
57
58
59
60

1
2
3 show high affinity for serum transferrin, binding the protein in one of the metal binding
4 sites (the N-lobe) as observed using HPLC-ICP-MS. Regarding cellular toxicity, our
5 studies indicate that in terms of reducing cell viability and proliferation, titanium present
6 as TiO₂ NPs or as Ti (IV) ions did not show differential toxicity risk. Both Ti species
7 cytotoxic effect was concentration dependent and was pronounced at concentrations
8 greater than 5 µg/mL. However, it can not be neglected that the release of ions from NPs
9 produced during wear of implants might contribute to the toxicity associated to the TiO₂
10 NPs and that both situations are difficult to be discriminated so far.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Transmission electron microscopy experiments have also shown that best solubilisation conditions for TiO₂ NPs includes the addition of protein rich media such as foetal serum with following ultrasonication. In any case, partial aggregation of the NPs in solution can be still detected. Regarding the cellular incorporation of TiO₂ NPs, the complementary use of ICP-MS and TEM permitted to address the rate of incorporation of Ti into the cells (<5%) and also the shape (a coated vesicle) indicating that the uptake of TiO₂ NPs occurred most likely via receptor-mediated endocytosis.

ACKNOWLEDGEMENTS

The work has been conducted under the financial support of the Gobierno del Principado de Asturias through Plan de Ciencia, Tecnología e Innovación (PCTI) del Principado de Asturias and co-financed by FEDER funds (ref. PC 10-27). The authors acknowledge also the financial support of the Spanish MICINN (Spanish ministry for science and innovation, grant number CTQ2011-23038).

REFERENCES

¹ J. J. Jacobs, J.L. Gilbert, R. M. Urban. Current concepts review-Corrosion of metal orthopaedic implants. *J Bone Joint Surg (Am)* 1998a, 80, 268-82.

- 1
2
3
4 ² R.M. Urban, J. J. Jacobs, M. J. Tomlinson, J. Gavrilovic, J. Black, M. Peoc'h . Dissemination of
5 wear particles to the liver, spleen, and abdominal lymph nodes of patients with hip or knee
6 replacement. *J Bone Joint Surg (Am)* 2000, **82**, 457-77.
- 7
8 ³ T. D. Richardson, S. J. Pineda, K. B. Strenge, T. A. Van Fleet, M. MacGregor, J. C. Milbrandt, J.
9 A. Espinosa, P. Freitag. Serum titanium levels after instrumented spinal arthrodesis. *Spine*, 2008,
10 **33**, 792-796.
- 11
12 ⁴ R. Ramachandran, S. B. Goodman, R. L. Smith. The effects of titanium and
13 polymethylmethacrylate particles on osteoblast phenotypic stability. *J. Biomed. Mater. Res. A*,
14 2006, **77**, 512–517.
- 15
16 ⁵ G.J. Atkins, K.J. Welldon, C.A. Holding, D.R. Haynes, D.W. Howie, D.M. Findlay. The
17 induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene
18 particles. *Biomaterials*, 2009, **30**, 3672–3681.
- 19
20 ⁶ Y. Zhang , W. Yu, X. Jiang, K. Lv, S. Sun, F. Zhang, Analysis of the cytotoxicity of
21 differentially sized titanium dioxide nanoparticles in murine MC3T3-E1 preosteoblasts. *J. Mater.*
22 *Sci.: Mater. Med.*, 2011, **22**, 1933–1945.
- 23
24 ⁷ N. J. Hallab. A review of the biologic effects of spine implant debris: Fact from fiction. *SAS*
25 *Journal*, 2009, **3**, 143-160.
- 26
27 ⁸ A. Sarmiento-González, J. M. Marchante-Gayón, J. M. Tejerina-Lobo, J. Paz-Jiménez, A. Sanz-
28 Medel. High-resolution ICP-MS determination of Ti, V, Cr, Co, Ni, and Mo in human blood and
29 urine of patients implanted with a hip or knee prosthesis. *Anal. Bioanal. Chem.*, 2008, **391**, 2583-
30 2589.
- 31
32 ⁹ Y. Nuevo Ordoñez, M. Montes Bayón, E. Blanco González, J. Paz Aparicio, J. D. Raimundez, J.
33 M. Tejerina Lobo, M. A. Peña, A. Sanz Medel. Titanium release in serum of patients with
34 different bone fixation implants and its interaction with serum biomolecules at physiological
35 levels. *Anal. Bioanal. Chem.*, 2011, **401**, 1-8.
- 36
37 ¹⁰ J. Soto Alvaredo, E. Blanco González, J. Paz Aparicio, A. Sanz-Medel, M. Montes-Bayón,
38 Comparative Ti release from different spinal implants. *Submitted*.
- 39
40 ¹¹ E. P. H. Chan, A. Mhawi, P. Clode, M. Saunders and L. Filgueira. Effects of titanium(IV) ions
41 on human monocyte-derived dendritic cells. *Metallomics*, 2009, **1**, 166–174.
- 42
43 ¹² N. J. Hallab, S. Anderson, M. Caicedo, A. Brasher, K. Mikecz, J. J. Jacobs. Effects of soluble
44 metals on human peri-implant cells. *J. Biomed. Mat. Res.*, 2005, **74A**, 124–140.
- 45
46 ¹³ S. Kittler, C. Greulich, J. Diendorf, M. Köller and M. Epple. Toxicity of Silver Nanoparticles
47 Increases during Storage Because of Slow Dissolution under Release of Silver Ions. *Chem. Mater.*,
48 2010, **22**, 4548–4554.
- 49
50 ¹⁴ M. Horie, K. Nishio, K. Fujita, H. Kato, A. Nakamura, S. Kinugasa, S. Endoh, A. Miyauchi, K.
51 Yamamoto, H. Murayama, E. Niki, H. Iwahashi, Y. Yoshida, J. Nakanishi. Ultrafine NiO particles
52
53
54
55
56
57
58
59
60

- 1
2
3
4 induce cytotoxicity in vitro by cellular uptake and subsequent Ni(II) release. *Chem. Res. Toxicol.*,
5 2009, **22**, 1415–1426.
- 6
7 ¹⁵ T. M. Benn , P. Westerhoff. Nanoparticle Silver Released into Water from Commercially
8 Available Sock Fabrics. *Environ. Sci. Technol.*, 2008, **42**, 4133–4139.
- 9
10 ¹⁶ O. Addison, A. J. Davenport, R. J. Newport, S. Kalra, M. Monir, J. F. W. Mosselmans, D.
11 Proops and R. A. Martin. Do ‘passive’ medical titanium surfaces deteriorate in service in the
12 absence of wear? *J. R. Soc. Interface*, 2012, **9**, 3161-3164.
- 13
14 ¹⁷ M. Horie, H. Kato, K. Fujita, S. Endoh, H. Iwahashi. In vitro evaluation of cellular response
15 induced by manufactured nanoparticles. *Chem. Res. Toxicol.*, 2012, **25**, 605-6019.
- 16
17 ¹⁸ A.D. Tinoco, A.M. Valentine. Ti(IV) binds to human serum transferrin more tightly than does
18 Fe(III). *J. Am. Chem. Soc.*, 2005, **127**, 11218-11219.
- 19
20 ¹⁹ J. Renau, L. Megías Eds. Manual de Técnicas de Microscopía Electrónica (M. E.T.).
21 Aplicaciones Biológicas, Editorial Universidad de Granada. ISBN84-338-2470-8.1998.
- 22
23 ²⁰ K. Davda, F. V. Lali, B. Sampson, J. A. Skinner, A. J. Hart. An analysis of metal ion levels in
24 the joint fluid of symptomatic patients with metal-on metal hip replacements *J. Bone. Joint. Surg.*
25 2011, **93**, 738-745.
- 26
27 ²¹ Z. Ji, X. Jin, S. George, T. Xia, H. Meng, X. Wang, E. Suarez, H. Zhang, E. M. V. Hoek, H.
28 Godwin, A. E. Nel, J. I. Zink. Dispersion and Stability Optimization of TiO₂ Nanoparticles in Cell
29 Culture Media. *Environ. Sci. Technol.*, 2010, **44**, 7309-7314
- 30
31 ²² R. Tedja, M. Lim, R. Amal, C. Marquis. Effects of serum adsorption on cellular uptake profile
32 and consequent impact of titanium dioxide nanoparticles on human lung cell lines. *ACS Nano*,
33 2012, **6**, 4083-4093.
- 34
35 ²³ Y. Nuevo-Ordoñez, M. Montes-Bayón, E. Blanco González, A. Sanz-Medel. Titanium
36 preferential binding sites in human serum transferrin at physiological concentrations. *Metallomics*,
37 2011, **3**, 1297-1303.
- 38
39 ²⁴ A.L. Di Virgilio, M. Reigosa, P.M. Arnal, M. F.L. de Mele. Comparative study of the cytotoxic
40 and genotoxic effects of titanium oxide and aluminium oxide nanoparticles in Chinese hamster
41 ovary (CHO-K1) cells. *J. Hazard. Mater.* 2009, **177**, 711–8.
- 42
43 ²⁵ G. Huajian, S. Wendong, L. B. Freund LB. Mechanics of receptormediated endocytosis. *Proc*
44 *Natl Acad Sci USA*. 2005, **102**, 9469–74.
- 45
46 ²⁶ I. Pujalté, I. Passagne, B. Brouillaud, M. Tréguer, E. Durand, C. Ohayon-Courtès, and B.
47 L’Azou. Cytotoxicity and oxidative stress induced by different metallic nanoparticles on human
48 kidney cells. *Part. Fibre Toxicol.*, 2011, **8**:10.
- 49
50 ²⁷ A.L. Di Virgilio, M. Reigosa, M.F.L. de Mele, *J. Biomed. Mater. Res. A*. Response of UMR
51 106 cells exposed to titanium oxide and aluminum oxide nanoparticles. 2010, **92A**, 80–86.
- 52
53
54
55
56
57
58
59
60

1
2
3
4 ²⁸ C.P. Case, V.G. Langkamer, C. James, M. R. Palmer, A. J. Kemp, P. F. Heap, L. Solomon.
5 Widespread dissemination of metal debris from implants. *J. Bone Joint Surg. [Br]* 1994, **76B**,
6 701-712.
7

8 ²⁹ N.J. Hallab, J.J. Jacobs. Biological effects of implants debris. *Bull. NYU Hosp. Jt .Dis.*, 2009,
9 **67**, 182-188.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

LEGENDS OF FIGURES

Figure 1. Transmission electron microscopy (TEM) photograph of solubilised TiO₂ NPs in human serum after sonication.

Figure 2. Titanium speciation in human serum after incubation with TiO₂ NPs and elimination of the remaining particles using anion exchange HPLC-ICP-MS. Sulphur monitoring for protein identification (pale blue trace), titanium (dark blue trace) and iron (pink trace).

Figure 3. Transmission electron microscopy (TEM) photograph of HT29 cells exposed to solubilised TiO₂ NPs (10 µg mL⁻¹). A) Photograph showing the cell cultures and the intracellular space, B and C) magnifications of specific parts of the cell culture.

Figure 4. Studies of cell viability (A and B) and proliferation (C) on MC3T3 murine osteoblasts using different Ti concentrations either as TiO₂ (NPs) and Ti(IV)-citrate complexes. A) MTT assay, B) Trypan Blue and C) Hoechst (***) p<0.001).

Table 1. Quantitative analysis of the solubilized Ti (measured by ICP-MS) from TiO₂ nanoparticles (21 nm) incubated in human serum for 7 days at 21 ± 2 °C.

Ti (incubation solution) (µg/mL)	Ti (in serum) (ng/mL)	% of Ti
0	1.5 ± 0.3	-
10.7	72 ± 10	0.67
29.8	158 ± 25	0.53
48.6	395 ± 35	0.82

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58





Figure 1




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58



Metallomics Accepted Manuscript

Figure 2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58




Metallomics Accepted Manuscript


Figure 3

Metallomics

A)



B)



C)




Figure 4